MetaCap

Evommune (EVMN) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evommune is the larger company by market cap ($291.1 million vs $264.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVMN-43.04%VCRE-42.12%
+25%-19%-63%
Jul 6, 20261 yearNov 20, 2026
EVMN-46.71%VCRE-31.75%
+15%-25%-65%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVMN versus VCRE key metrics
MetricEVMNVCRE
Share price$7.04$9.41
Market cap$291.10M$264.89M
1-day change-2.76%-5.09%
YTD return-58.88%—
1-year return-62.37%—
EPS (TTM)$-3.83$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.00M—
Revenue growth (YoY)+85.71%—
Net income (latest FY)$-68.87M—
Operating margin-623.62%—
Net margin-529.77%—
52-week high$33.20$17.80
52-week low$4.94$7.88
Distance from 52-week high-78.80%-47.16%
Analyst consensusbuystrong_buy
Avg. price target upside+210.94%+158.90%
Average volume841.65K23.31K
Shares outstanding41.35M28.16M
Employees4850
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

EVMN vs VCRE FAQ

Which is bigger, Evommune or Vicore Pharma AB?

Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $264.89M for Vicore Pharma AB (VCRE).

Are Evommune and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons